Table 2.
Correlation of prostate KLK3 mRNA expression and preoperative circulating serum PSA levels to clinical parameters in patients with primary prostate tumors from the TCGA dataset (n = 497).
| r | p | n | ||||
|---|---|---|---|---|---|---|
| KLK3 | Preop. cPSA | KLK3 | Preop. cPSA | KLK3 | Preop. cPSA | |
| KLK3 | 1 | 0.0119 | 0 | 1 | 497 | 482 |
| Preop. cPSA value | 0.0119 | 1 | 0.79 | 0 | 482 | 482 |
| days to birth | 0.1107 | 0.0174 | 0.01 | 0.71 | 486 | 471 |
| age at initial pathologic diagnosis | −0.1189 | −0.0294 | 0.01 | 0.52 | 497 | 482 |
| number of LNs positive by H&E | −0.1594 | 0.2250 | 0.00 | 6.47E-06 | 406 | 394 |
| numeric pathologic T | −0.3013 | 0.3087 | 9.7E-12 | 5.97E-12 | 490 | 475 |
| numeric clinical T | −0.1606 | 0.2034 | 0.00 | 4.45E-05 | 405 | 397 |
| Gleason pattern secondary | −0.2389 | 0.0788 | 7E-08 | 0.084 | 497 | 482 |
| Gleason pattern primary | −0.2664 | 0.2605 | 1.6E-09 | 6.44E-09 | 497 | 482 |
| Gleason score | −0.3403 | 0.2230 | 6.2E-15 | 7.62E-07 | 497 | 482 |
Abbreviations: cPSA: circulating serum PSA; LN: lymph nodes; H&E: hematoxylin and eosin; numeric pathologic T: numeric pathologic T stage; numeric clinical T: numeric clinical T stage.